Understanding Fuchs Endothelial Corneal Dystrophy (FECD)
Fuchs endothelial corneal dystrophy (FECD) affects the corneal endothelium and can lead to corneal swelling and loss of visual clarity. Research may address disease-associated biology involving TCF4 or SLC4A11, with the model and genetic context defined for the study.
At MuriPhys, we provide comprehensive preclinical research services to develop innovative therapies aimed at halting or reversing the progression of FECD, including cell-based therapies, gene editing, and pharmacological treatments.
Precision Drug Delivery for Ocular Models
For FECD research, ocular administration is selected for the test article and anatomical question. Corneal targeting and distribution are assessed with suitable methods.
- Intracameral (IC) Injection – Direct delivery into the anterior chamber for localized treatment of endothelial cells.
- Intravitreal (IVT) Injection – Targets the posterior segment of the eye for broader distribution.
- Topical Administration (Eye Drops) – Non-invasive delivery for repeated dosing regimens, simulating patient use.
- Subconjunctival Injection – Facilitates sustained drug release to the corneal region.
These methods allow for flexible delivery approaches, accommodating a range of therapeutic modalities from gene therapy to small molecules.
Imaging and Functional Assays
FECD studies require endpoints suited to corneal structure and function. Imaging and visual assessments are selected for the disease model and the treatment question.
- Optical Coherence Tomography (OCT) – Provides high-resolution imaging of corneal layers, enabling the assessment of swelling and structural changes.
These imaging techniques offer quantitative data crucial for evaluating the effectiveness of emerging FECD therapies.
Electrophysiology – Assessing Ocular Function
ERG records retinal electrical responses to light and can be included when retinal function is relevant. OCT provides structural imaging. Corneal endpoints and interpretation are defined separately for the FECD study.
- ERG Testing: Characterizes retinal responses to light when that endpoint is relevant to the study.
- OCT Imaging: Can characterize corneal structure, including thickness or edema where supported by the selected imaging configuration.
Functional and structural measurements are interpreted together with the model, controls and optical conditions.
Behavioral and Functional Vision Assays
To complement ocular imaging, MuriPhys offers a range of behavioral and functional vision tests to assess the impact of FECD on animal models:
- Optodrum: Assesses optomotor visual performance, interpreted with ocular structure and the study conditions.
- Open Field: Assesses exploratory and locomotor behavior. Interpretation considers possible visual, motor and anxiety-related influences.
These functional tests allow researchers to correlate corneal pathology with visual deficits, improving translational relevance.
Why Choose MuriPhys for FECD Research?
Contact us to explore how MuriPhys can enhance your FECD research initiatives.